CN112513089A - 抗cd73抗体、其抗原结合片段及应用 - Google Patents

抗cd73抗体、其抗原结合片段及应用 Download PDF

Info

Publication number
CN112513089A
CN112513089A CN201980050242.2A CN201980050242A CN112513089A CN 112513089 A CN112513089 A CN 112513089A CN 201980050242 A CN201980050242 A CN 201980050242A CN 112513089 A CN112513089 A CN 112513089A
Authority
CN
China
Prior art keywords
seq
antibody
antigen
variable region
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050242.2A
Other languages
English (en)
Inventor
曹卓晓
付雅媛
许志宾
张利敏
胡齐悦
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112513089A publication Critical patent/CN112513089A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

提供抗CD73抗体、其抗原结合片段及应用。具体地，提供包含特定CDR区的鼠源、嵌合或人源化抗CD73抗体及其抗原结合片段。还提供包含所述抗CD73抗体或其抗原结合片段的药物组合物，以及其作为CD73相关疾病诊断剂和治疗药物的用途。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201980050242.2A 2018-11-12 2019-11-11 抗cd73抗体、其抗原结合片段及应用 Pending CN112513089A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811337068 2018-11-12
CN2018113370683 2018-11-12
PCT/CN2019/117114 WO2020098599A1 (zh) 2018-11-12 2019-11-11 抗cd73抗体、其抗原结合片段及应用

Publications (1)

Publication Number Publication Date
CN112513089A true CN112513089A (zh) 2021-03-16

Family

ID=70730768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050242.2A Pending CN112513089A (zh) 2018-11-12 2019-11-11 抗cd73抗体、其抗原结合片段及应用

Country Status (11)

Country Link
US (1) US20220220218A1 (zh)
EP (1) EP3882268A4 (zh)
JP (1) JP2022509930A (zh)
KR (1) KR20210093255A (zh)
CN (1) CN112513089A (zh)
AU (1) AU2019381219A1 (zh)
BR (1) BR112021007902A2 (zh)
CA (1) CA3118775A1 (zh)
MX (1) MX2021005396A (zh)
TW (1) TW202017945A (zh)
WO (1) WO2020098599A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045659A (zh) * 2021-03-18 2021-06-29 上海近岸科技有限公司 抗cd73人源化抗体
WO2023109962A1 (zh) * 2021-12-17 2023-06-22 三生国健药业（上海）股份有限公司 结合人cd73的抗体、其制备方法和用途
CN116813786A (zh) * 2023-08-03 2023-09-29 贝达药业股份有限公司 抗cd73抗体及其应用
CN116903744A (zh) * 2022-08-12 2023-10-20 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
WO2024077774A1 (zh) * 2022-10-13 2024-04-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294436A (en) 2020-01-03 2022-09-01 Incyte Corp Anti-cd73 antibodies and their uses
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
TW202400242A (zh) * 2022-03-14 2024-01-01 大陸商上海華奧泰生物藥業股份有限公司 抗體藥物偶聯物及其應用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (zh) * 2014-11-10 2017-08-01 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
WO2018137598A1 (en) * 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
GB2538120A (en) * 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
EA035766B1 (ru) * 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Антитело к cd73 и его применения
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CA3007646A1 (en) * 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
SG11201806861SA (en) 2016-03-04 2018-09-27 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (zh) * 2014-11-10 2017-08-01 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途
WO2018137598A1 (en) * 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045659A (zh) * 2021-03-18 2021-06-29 上海近岸科技有限公司 抗cd73人源化抗体
WO2023109962A1 (zh) * 2021-12-17 2023-06-22 三生国健药业（上海）股份有限公司 结合人cd73的抗体、其制备方法和用途
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
CN116903744A (zh) * 2022-08-12 2023-10-20 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024077774A1 (zh) * 2022-10-13 2024-04-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
CN116813786A (zh) * 2023-08-03 2023-09-29 贝达药业股份有限公司 抗cd73抗体及其应用

Also Published As

Publication number Publication date
CA3118775A1 (en) 2020-05-22
AU2019381219A1 (en) 2021-05-27
EP3882268A4 (en) 2022-08-17
EP3882268A1 (en) 2021-09-22
TW202017945A (zh) 2020-05-16
BR112021007902A2 (pt) 2021-11-16
MX2021005396A (es) 2021-07-06
JP2022509930A (ja) 2022-01-25
US20220220218A1 (en) 2022-07-14
WO2020098599A1 (zh) 2020-05-22
KR20210093255A (ko) 2021-07-27

Similar Documents

Publication Publication Date Title
CN112513089A (zh) 抗cd73抗体、其抗原结合片段及应用
US11680100B2 (en) B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN109983032B (zh) Tim-3抗体、其抗原结合片段及医药用途
CN112513087B (zh) 抗cd38抗体、其抗原结合片段及医药用途
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
EP4095157A1 (en) Anti-angptl3 antibody and use thereof
CN114746440A (zh) 新型多肽复合物
WO2021098822A1 (zh) 一种双特异性抗体
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
TWI843799B (zh) 抗pd-1抗體、其抗原結合片段及醫藥用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045560

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210316